Safety and efficacy of a multi-tumor-associated antigen-specific T cell therapy in pancreatic cancer patients
Active Grant Awarded
- Award ID
- R01FD008756
- Recipient
-
Marker Therapeutics Inc. UEI CK3KR85CSP23
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $645,493
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date 4% complete
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Houston, TX 77021, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services Food and Drug Administration awarded Marker Therapeutics Inc. $645,493 on September 24, 2026, under Food and Drug Administration Research (CFDA 93.103) to fund a Phase 1 clinical trial of the MT-601 T-cell therapy in pancreatic cancer. The Office of Medical Products and Tobacco is the listed alternate office within the funding agency. The award funds PANACEA (NCT06549751), a single-center, open-label trial evaluating the safety and efficacy of MT-601 administered during maintenance capecitabine following FFX or NLX in patients with locally advanced unresectable pancreatic cancer. The trial uses a modified 3+3 dose escalation followed by expansion at the recommended dose. Specific Aim 1 determines the maximum tolerated dose and evaluates progression-free survival and duration of response. Specific Aim 2 correlates biological characteristics of MT-601, including T cell expansion, persistence, clonality, and anti-tumor immune effects, with clinical outcomes. The planned follow-on is a randomized pivotal study comparing MT-601 plus maintenance chemotherapy against maintenance chemotherapy alone. Place of performance is Houston, TX 77021, USA. The period of performance ends August 31, 2030. The assistance type is Grant.
Description
- Abstract
- Pancreatic cancer (PC) is an orphan disease affecting approximately 67,440 people annually in the US. With a 5-year relative survival of only 13% for all stages combined and 3.2% for metastatic disease, PC represents one of the most aggressive malignancies. Although surgical resection provides the best curative option, 200 patients across 7 cancer indications, without cytokine release syndrome, neurotoxicity, or dose-limiting toxicities. MT-601 represents an improved product with the addition of WT1, higher dosing (400×10⁶ cells VS 20×10⁶), and enhanced manufacturing yielding 4X increased potency. Therefore, marker proposes a phase 1, single-center, open-label clinical trial (panacea, NCT# 06549751) to evaluate the safety and efficacy of MT-601 administered during maintenance capecitabine following FFX or NLX in patients with locally advanced unresectable PC. The trial includes dose escalation using a modified 3+3 design followed by expansion at the recommend dose. Specific aim 1 will assess safety and efficacy of MT-601 in combination with maintenance capecitabine, determining the maximum tolerated dose and evaluating progression-free survival and duration of response. Specific aim 2 will correlate biological characteristics of MT- 601 with clinical outcomes, including T cell expansion, persistence, clonality, and anti-tumor immune effects. Successful completion of this trial will provide critical dosing, safety, and efficacy data necessary to advance MT- 601 to a randomized pivotal study comparing MT-601 plus maintenance chemotherapy versus maintenance chemotherapy alone, ultimately advancing this therapy toward market approval for PC patients.
Quick answers
Who received award R01FD008756?
R01FD008756 was awarded to Marker Therapeutics Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 24, 2026.
How much is award R01FD008756 worth?
$645,493 has been obligated on R01FD008756.
Which agency awarded R01FD008756?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008756, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award